In oncology research, cGAS -STING activation has been shown to contribute to antitumor effects by triggering spontaneous antitumor immunity, enhancing senescence in premalignant cells, facilitating conventional cancer therapy responses, and inducing regulated cell death through interferon (IFN)-dependent and IFN-independent pathways [15, 16]. This evidence concerns the gene STING1 and cancer.